Highlights MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-29 pm EDT			5-day change	1st Jan Change
3.08 ^USD	+0.98%		-8.61%	-46.90%

Apr. 11	MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	CI
Apr. 11	MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	Apr. 11	CI
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	Apr. 11	CI
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	Mar. 26	CI
MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13	CI
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023	Dec. 11	CI
Ex-dividend day	Nov. 15	FA
Earnings Flash (MEIP) MEI PHARMA Posts Q1 Revenue $65.3M	Nov. 09	MT
MEI Pharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 09	CI
MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023	Nov. 06	CI
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023	Nov. 02	CI
Anson Funds hires Legion Partners' Gupta to build out activism strategy	23-10-03	RE
MEI Pharma Rose in After-Hours Activity Tuesday Following Fiscal 2023 Results That Showed Higher Sales, Narrower Net Loss	23-09-27	MT
MEI Pharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-26	CI
MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab in Patients with Previously Treated Metastatic Colorectal Cancer	23-08-16	CI
MEI Pharma, Inc. cancelled the acquisition of Infinity Pharmaceuticals, Inc. from The Vanguard Group, Inc. and others.	23-07-22	CI
MEI Pharma Shareholders Anson Funds, Cable Car Capital Seek to Remove 'Entire' Board While Infiniti Deal Progresses	23-07-17	MT
Infinity Pharmaceuticals Shareholders Approve MEI Pharma Merger Deal	23-07-14	MT
MEI Pharma Pushes Back Special Shareholder Meeting to Decide on Pending Infinity Pharmaceuticals Merger	23-07-14	MT
MEI Pharma Urges Shareholders to Vote for Pending Infinity Pharmaceuticals Merger	23-07-11	MT
MEI Pharma Reiterates Support for Infinity Deal After Anson, Cable Car Criticism	23-06-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Highlights

Filters